Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Maxim Group Downgrades Inovio Pharmaceuticals (INO) to Hold
August 9, 2016 6:49 AM EDTMaxim Group downgraded Inovio Pharmaceuticals (NASDAQ: INO) from Buy to Hold, citing few drivers near-term for upside.
Analyst Jason McCarthy commented:
Inovio reported 2Q16 earnings (*next bullet). What's critical now is the fact that Inovio is burning up to $100M a year, in our view. We recognize Inovio does have revenues that partially offset the burn rate. These include license fees like the one paid upfront by AstraZenca ($27M) for the VGX-3100 technology (in this case INO-3112). We believe in Inovio's platform and technology, but the key challenge that we... More
Inovio Pharma (INO) Misses Q2 EPS by 5c
August 8, 2016 8:04 AM EDTInovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.26), $0.05 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.95 million.
As of June 30, 2016, cash and cash equivalents and short-term investments were $134.5 million compared with $163.0 million as of... More
